Back to Journals » International Journal of Nephrology and Renovascular Disease » Volume 5

Long-term effects of aliskiren on blood pressure and the renin-angiotensin-aldosterone system in hypertensive hemodialysis patients

Authors Morishita Y, Watanabe M, Hanawa S, Iimura O, Tsunematsu S, Ishibashi K, Kusano

Received 25 January 2012

Accepted for publication 26 February 2012

Published 21 March 2012 Volume 2012:5 Pages 45—51


Review by Single-blind

Peer reviewer comments 4

Yoshiyuki Morishita1, Minami Watanabe1, Shiho Hanawa1, Osamu Iimura2, Sadao Tsunematsu3, Kenichi Ishibashi4, Eiji Kusano1

1Division of Nephrology, Department of Medicine, Jichi Medical University, Tochigi, Japan; 2Kumakura Clinic, Tochigi, Japan; 3Yuki Clinic, Ibaragi, Japan; 4Department of Medical Physiology, Meiji Pharmaceutical University, Tokyo, Japan

Objective: The long-term effects of aliskiren in hypertensive hemodialysis patients remain to be elucidated.
Design: In this post hoc analysis, we followed up 25 hypertensive hemodialysis patients who completed 8-week aliskiren treatment in a previous study for 20 months to investigate the blood pressure-lowering effect and inhibitory effect on the renin-angiotensin-aldosterone system.
Results: Among the 25 patients, eleven patients continued with aliskiren treatment. Blood pressure (± standard deviation) decreased from 175 ± 18/80 ± 11 mmHg at baseline to 156 ± 20/76 ± 9 mmHg at month 20. Plasma renin activity, angiotensin I, and angiotensin II decreased from baseline to month 20 (plasma renin activity (ng/mL/h): 2.3 ± 2.6 to 0.3 ± 0.4 (P < 0.05), angiotensin I (pg/mL): 909.1 ± 902.5 to 41.5 ± 14.8 (P < 0.05), angiotensin II (pg/mL): 41.5 ± 45.8 to 11.0 ± 4.9 (P < 0.05).
Conclusion: Long-term treatment with aliskiren provides effective blood pressure lowering and inhibition of the renin-angiotensin-aldosterone system, which are sustained over 20 months in hypertensive hemodialysis patients.

Keywords: aliskiren, blood pressure, renin, angiotensin, aldosterone, hemodialysis patients, long-term effects

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]